LYCA
Lycia Therapeutics, Inc.
Set alert
- YTD
- -12.00%
- 1 year
- -12.00%
- Open
- 26.28
- Prev close
- 27.73
- Mkt cap
- 1.38B
- Vol
- 202.45K
- Avg vol
- 856.50K
- EPS
- -1.04
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 25.66
- High
- 27.59
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 39.24%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 27.55
- 200-d avg
- 27.55
- 1y target
- 0.00
News
4 days ago globenewswire.com
Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of…
6 days ago barrons.com
Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere
As investors wait for the Claude developer to file its official IPO paperwork, several biotechs are going public and doing just fine.
1 week ago seekingalpha.com
U.S. IPO Weekly Recap: Trickle Of Biotech Activity Continues Amid Tech Sell-Off
One biotech IPO debuted this week, while four IPOs submitted initial filings, including two sizable biotech filings. One IPO is currently scheduled for the week ahead as investors continue to hold…
1 week ago globenewswire.com
Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of…
1 week ago reuters.com
Drug developer Lycia Therapeutics targets $938 million valuation in US IPO
Drug developer Lycia Therapeutics targets $938 million valuation in US IPO